July 30 (Reuters) - Medical device maker Dexcom ( DXCM )

raised its full-year revenue forecast and beat quarterly

estimates on Thursday, banking on sustained demand for its

continuous glucose monitors that track blood sugar levels,

sending shares of the company up over 4% in extended trading.

Here are the details:

* Rising awareness of diabetes care, improved insurance

coverage and a wider consumer shift towards finger-prick-free

technology have boosted demand for continuous glucose monitors,

intensifying competition among market leaders Dexcom ( DXCM ), Medtronic ( MDT )

and Abbott Laboratories ( ABT ).

* Dexcom ( DXCM ) reported second-quarter revenue of $1.31 billion,

up 13% over a year earlier. Analysts on average had estimated

$1.29 billion, according to data compiled by LSEG.

* It posted quarterly adjusted profit of 70 cents per share,

compared with the estimate of 61 cents.

* The company expects annual revenue to be between $5.18

billion and $5.25 billion, compared with $5.16 billion to $5.25

billion forecast earlier, and analysts' estimate of $5.22

billion.

* Dexcom ( DXCM ) said in May it would appoint two independent

directors and revamp a key board committee in collaboration with

activist investor Elliott Investment Management.